CXCR4 and PD-1 Expression in Head and Neck Cancer with Perineural Spread

Abstract

Background Perineural spread (PNS) is a marker of aggressiveness and has been shown to occur in cranial nerves due to advanced mucosal and cutaneous head and neck cancer. Receptors CXC chemokine receptor 4 (CXCR4) and programmed cell death-1 (PD-1) have been shown to be overexpressed in a variety of cancers with PNS, with the inhibition of these pathways offering a potential future treatment.

Methods Retrospective immunohistochemical staining for the CXCR4 and PD-1 receptors was performed on 28 head and neck specimens that demonstrated PNS from January 2017 to August 2017, at Royal Brisbane and Women's Hospital, Brisbane, Australia.

Results CXCR4 staining was positive in 52 and 60% of the squamous cell carcinoma (SCC) and adenoid cystic carcinoma PNS specimens, respectively. Cutaneous SCC tumors with no PNS stained positively in 33%. No significant staining for PD-1 in peritumoral lymphocytes or tumor specimens was seen.

Conclusion CXCR4 is overexpressed in advanced skin cancer and head and neck tumors that demonstrated PNS to large cranial nerves. Overall, these results provide strong support for using CXCR4 as a biomarker and further investigation of immunotherapeutic agents that could inhibit tumor progression via targeting CXCR4 expression.

Keywords

CXCR4 - PD-1 - head and neck cancer - plerixafor - perineural spread - adenoid cystic carcinoma - squamous cell carcinoma

• References

• 1 Buettner PG, Raasch BA. Incidence rates of skin cancer in Townsville, Australia. Int J Cancer 1998; 78 (05) 587-593
• 2 Warren TA, Whiteman DC, Porceddu SV, Panizza BJ. Insight into the epidemiology of cutaneous squamous cell carcinoma with perineural spread. Head Neck 2016; 38 (09) 1416-1420
• 3 Jackson JE, Dickie GJ, Wiltshire KL. , et al. Radiotherapy for perineural invasion in cutaneous head and neck carcinomas: toward a risk-adapted treatment approach. Head Neck 2009; 31 (05) 604-610
• 4 Balamucki CJ, Mancuso AA, Amdur RJ. , et al. Skin carcinoma of the head and neck with perineural invasion. Am J Otolaryngol 2012; 33 (04) 447-454
• 5 Jeong W-J, Choi IJ, Park M-W. , et al. CXCR4 antagonist inhibits perineural invasion of adenoid cystic carcinoma. J Clin Pathol 2014; 67 (11) 992-998
• 6 Amit M, Binenbaum Y, Sharma K. , et al. Analysis of failure in patients with adenoid cystic carcinoma of the head and neck. An international collaborative study. Head Neck 2014; 36 (07) 998-1004
• 7 van der Wal JE, Becking AG, Snow GB, van der Waal I. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head Neck 2002; 24 (08) 779-783
• 8 Zhang L, Hua Q, Tang K, Shi C, Xie X, Zhang R. CXCR4 activation promotes differentiation of human embryonic stem cells to neural stem cells. Neuroscience 2016; 337: 88-97
• 9 Rave-Fränk M, Tehrany N, Kitz J. , et al. Prognostic value of CXCL12 and CXCR4 in inoperable head and neck squamous cell carcinoma. Strahlenther Onkol 2016; 192 (01) 47-54
• 10 Oliveira-Neto HH, Silva ET, Leles CR. , et al. Involvement of CXCL12 and CXCR4 in lymph node metastases and development of oral squamous cell carcinomas. Tumour Biol 2008; 29 (04) 262-271
• 11 Albert S, Hourseau M, Halimi C. , et al. Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue. Oral Oncol 2012; 48 (12) 1263-1271
• 12 Salgia R, Weaver RW, McCleod M. , et al. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. Invest New Drugs 2017; 35 (03) 334-344
• 13 Popp FC, Popp MC, Zhao Y. , et al. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease. BMC Cancer 2017; 17 (01) 229
• 14 Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 2016; 9: 5023-5039
• 15 Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2015; 21 (01) 24-33
• 16 Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007; 1768 (04) 952-963
• 17 Samara GJ, Lawrence DM, Chiarelli CJ. , et al. CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 2004; 214 (02) 231-241
• 18 Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 1998; 279 (5349): 381-384
• 19 Panizza BJ. An overview of head and neck malignancy with perineural spread. J Neurol Surg B Skull Base 2016; 77 (02) 81-85
• 20 Lin C, Tripcony L, Keller J, Poulsen M, Dickie G. Cutaneous carcinoma of the head and neck with clinical features of perineural infiltration treated with radiotherapy. Clin Oncol (R Coll Radiol) 2013; 25 (06) 362-367
• 21 Speetjens FM, Liefers GJ, Korbee CJ. , et al. Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron 2009; 2 (01) 1-7
• 22 Linedale R, Schmidt C, King BT. , et al. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients. PLoS One 2017; 12 (04) e0175755
• 23 Slater NA, Googe PB. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. J Cutan Pathol 2016; 43 (08) 663-670
• 24 Zushi Y, Noguchi K, Hashitani S. , et al. Relations among expression of CXCR4, histological patterns, and metastatic potential in adenoid cystic carcinoma of the head and neck. Int J Oncol 2008; 33 (06) 1133-1139
• 25 Cashen AF, Rettig M, Gao F. , et al. Phase I/II study of intravenous plerixafor added to a mobilization regimen of granulocyte colony-stimulating factor in lymphoma patients undergoing autologous stem cell collection. Biol Blood Marrow Transplant 2017; 23 (08) 1282-1289
• 26 Douglas KW, Gilleece M, Hayden P. , et al. UK consensus statement on the use of plerixafor to facilitate autologous Peripheral Blood Stem Cell collection to support high-dose chemoradiotherapy for patients with malignancy. J Clin Apher 2018; 33 (01) 46-59
• 27 Hong J-S, Pai H-K, Hong K-O. , et al. CXCR-4 knockdown by small interfering RNA inhibits cell proliferation and invasion of oral squamous cell carcinoma cells. J Oral Pathol Med 2009; 38 (02) 214-219
• 28 Yu T, Wu Y, Huang Y. , et al. RNAi targeting CXCR4 inhibits tumor growth through inducing cell cycle arrest and apoptosis. Mol Ther 2012; 20 (02) 398-407